AbstractTo explore how early cancers can be detected prior to clinical signs or symptoms, we assessed prospectively collected serial plasma samples from the Atherosclerosis Risk in Communities study, ...

Abstract. The integration of artificial intelligence (AI) in cancer research has significantly advanced radiology, pathology, and multimodal approaches, offering unprecedented capabilities in image ...

Abstract. Radiomics, the extraction of quantitative data from images, holds promise for noninvasively characterizing tumor phenotypes. Tools like LIFEx have improved the accessibility, transparency, ...

A new AI platform turns a general-purpose language model into an autonomous clinical agent that can analyze diagnostic data, interpret imaging and pathology, and generate treatment plans for patients ...

KRAS pathways are frequently upregulated in cancers bearing KRAS mutations or by other signaling modifications. Also, resistance to KRAS G12C inhibitors and other KRAS/RAF/MEK pathway drugs is ...

Abstract. Background: KRAS mutations are the most frequently encountered driver oncogene, involved in ~25% of all human cancers [1,2]. KRASG12D is the predominant KRAS mutation isoform, detected in ...

Doxorubicin-naïve patients with metastatic soft-tissue sarcoma were enrolled in this phase Ib study. Every 21 days, subjects received ribociclib daily for 7 days followed by 3 days of no treatment ...

The FDA removed the Risk Evaluation and Mitigation Strategies (REMS) requirements for approved BCMA- and CD19-targeting chimeric antigen receptor (CAR) T-cell therapies. The FDA can require a REMS ...

Homologous recombination is a high-fidelity DNA repair mechanism essential for maintaining genome stability. Impairment of this pathway, often due to BRCA1 or BRCA2 inactivation, leads to homologous ...

Abstract. The Hippo pathway, a critical cell proliferation regulator, remains an underexplored oncogenic pathway in precision oncology. It is executed through YAP1/TAZ co-activators and the TEAD ...

Abstract. Introduction: Antibody and peptide-conjugated drugs are rapidly entering the clinic for the treatment of patients with early and advanced breast cancer. These drugs are designed to achieve ...

The FDA today granted accelerated approval to linvoseltamab (Lynozyfic, Regeneron) for adults with relapsed or refractory multiple myeloma who have already received at least four therapeutic regimens.